Molecular Breast Imaging Has Greater Sensitivity Over Mammography, Ultrasound and MRI for Invasive Lobular Carcinoma

Wednesday, December 3, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

CHICAGO, Dec. 2 Breast-Specific Gamma Imaging (BSGI) hasbeen proven to be a highly sensitive imaging technique for the diagnosis ofinvasive lobular carcinoma (ILC), a difficult to diagnose breast cancer. BSGIis a molecular breast imaging technique that can see lesions independent oftissue density and discover very early stage cancers. When compared tomammography, ultrasound and magnetic resonance imaging (MRI), BSGI has thegreatest sensitivity for detecting ILC, according to findings presented todayat the annual meeting of the Radiological Society of North America (RSNA).

"Our study compares the sensitivity of mammography, ultrasound, MRI andBSGI in the detection of ILC. We found BSGI to have the greatest sensitivityof all four techniques," said Dr. Rachel Brem, Director of Breast Imaging andIntervention at George Washington University Medical Center in Washington,D.C., and Vice Chair of the Department of Radiology.

This study was a retrospective multi-center study of women withbiopsy-proven pure ILC. Patients had imaging performed with mammography andBSGI. Ultrasound and MRI results, if performed, and pathologic tumor size wereincluded for analysis. The sensitivity of mammography, ultrasound, MRI andBSGI was determined for each modality and compared. Twenty-six women, ages 46to 82 (mean age of 62.8), with 28 biopsy proven pure ILC, mean size of 22.3mm(2mm -90mm) were included.

BSGI had the greatest sensitivity for the detection of ILC with asensitivity of 93 percent. Mammography, ultrasound and MRI demonstratedsensitivities of 79 percent, 68 percent and 83 percent, respectively.

The BSGI for the study was conducted using a Dilon 6800 Gamma Camera, ahigh-resolution, small field-of-view gamma camera, optimized to perform BSGI.With BSGI, the patient receives a pharmaceutical tracing agent that isabsorbed by all the cells in the body. Due to their increased rate ofmetabolic activity, cancerous cells in the breast absorb a greater amount ofthe tracing agent than the normal surrounding tissue and generally appear as"hot spots" on the BSGI image.

Dr. Brem has published many articles on breast cancer-related topics inher areas of interest, which include new technologies for the early diagnosisof breast cancer and BSGI.

"BSGI is an effective adjunct imaging modality for the diagnosis of breastcancer and has a promising role in the diagnosis of ILC," said Dr. Brem.

About Dilon Technologies

Dilon Technologies Inc. is bringing innovative new medical imagingproducts to market. Dilon's cornerstone product, the Dilon 6800, is ahigh-resolution, small field-of-view gamma camera, optimized to perform BSGI,a molecular breast imaging procedure which images the metabolic activity ofbreast lesions through radiotracer uptake. Many leading medical centers aroundthe country are now offering BSGI to their patients, including: CornellUniversity Medical Center, New York; George Washington University MedicalCenter, Washington, D.C.; and The Rose, Houston.

For more information on Dilon Technologies please visit

SOURCE Dilon Technologies Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store